[go: up one dir, main page]

ES2153053T3 - Liposomas de eter-lipido y su uso terapeutico. - Google Patents

Liposomas de eter-lipido y su uso terapeutico.

Info

Publication number
ES2153053T3
ES2153053T3 ES95935710T ES95935710T ES2153053T3 ES 2153053 T3 ES2153053 T3 ES 2153053T3 ES 95935710 T ES95935710 T ES 95935710T ES 95935710 T ES95935710 T ES 95935710T ES 2153053 T3 ES2153053 T3 ES 2153053T3
Authority
ES
Spain
Prior art keywords
eter
liposomas
lipido
therapeutic use
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95935710T
Other languages
English (en)
Inventor
Eric Mayhew
Andrew S Janoff
Imran Ahmad
Suresh K Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ES2153053T3 publication Critical patent/ES2153053T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LIPIDOS DE ETER QUE TIENEN LA FORMULA (I), SE INCORPORAN EN LIPOSOMAS QUE CON UN LIPIDO DERIVATIZADO EN SU GRUPO DE CABECERA, Y OPCIONALMENTE UN ESTEROL Y UN LIPIDO NEUTRAL. LOS LIPOSOMAS PUEDEN USARSE PARA ADMINISTRAR LIPIDOS DE ETER A ANIMALES TALES COMO LOS SERES HUMANOS, POR EJEMPLO, PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS CANCEROSOS E INFLAMATORIOS.
ES95935710T 1994-10-14 1995-10-12 Liposomas de eter-lipido y su uso terapeutico. Expired - Lifetime ES2153053T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32304294A 1994-10-14 1994-10-14

Publications (1)

Publication Number Publication Date
ES2153053T3 true ES2153053T3 (es) 2001-02-16

Family

ID=23257529

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95935710T Expired - Lifetime ES2153053T3 (es) 1994-10-14 1995-10-12 Liposomas de eter-lipido y su uso terapeutico.

Country Status (15)

Country Link
US (1) US5762958A (es)
EP (1) EP0785773B1 (es)
JP (1) JPH10507450A (es)
KR (1) KR100381449B1 (es)
AT (1) ATE198419T1 (es)
AU (1) AU707414B2 (es)
CA (1) CA2199179A1 (es)
DE (1) DE69519802T2 (es)
DK (1) DK0785773T3 (es)
ES (1) ES2153053T3 (es)
FI (1) FI971494L (es)
GR (1) GR3035689T3 (es)
NO (1) NO316206B1 (es)
PT (1) PT785773E (es)
WO (1) WO1996011670A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965159A (en) * 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
US5932242A (en) * 1996-10-15 1999-08-03 The Liposome Company, Inc. Ether lipid-containing pharmaceutical compositions and therapeutic uses thereof
DE19829448A1 (de) * 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
ES2154560B1 (es) * 1998-09-16 2001-12-01 Lipotec Sa Composicion a base de derivados de cromanos y su uso para reducir quimicamente las reacciones oxidativas o inducidas por radicales libres.
EP1140112B1 (en) * 1998-12-21 2005-03-09 Inkeysa, S.A. Etherlysophospholipids for the treatment of chronic inflammatory diseases
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US8304395B2 (en) 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US8501701B2 (en) 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US8883761B2 (en) 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
CA2584537C (en) * 2004-10-19 2013-09-24 Hansjorg Eibl Formulations containing alkylphosphocholines using novel negative charge carriers
EA012138B1 (ru) * 2004-11-17 2009-08-28 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим Применение конъюгатов липидов при лечении заболеваний
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
CA2705785A1 (en) 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
ES2391226T3 (es) * 2006-12-20 2012-11-22 Alphaptose Gmbh Forma farmacéutica tópica que comprende compuestos de glicerol tri-sustituido
ES2594927T3 (es) 2010-02-18 2016-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para prevenir las metástasis cancerosas
US20150132369A1 (en) * 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN114469865B (zh) * 2022-03-17 2023-09-22 中国医学科学院输血研究所 一种与血细胞膜结合的脂质体药物载体及其制备方法和用途
WO2024126812A1 (en) 2022-12-15 2024-06-20 Lifesome Therapeutics, S.L. Carrier as a multifunctional system

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
US4163748A (en) * 1973-09-06 1979-08-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Propane-1,3-diol phosphatides and method of preparing the same
US4159988A (en) * 1974-08-06 1979-07-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic phospholipids, a process for their manufacture and their use
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3011738A1 (de) * 1980-03-26 1981-10-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerin-3-phosphorsaeurehalogenalkylester
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
JPS5972294A (ja) * 1982-10-18 1984-04-24 Hisaji Nakamura スピ−カ装置
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US4983397A (en) * 1985-08-19 1991-01-08 Board Of Regents, University Of Texas System Pharmaceutical compositions consisting of acylated phospholipids
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4965391A (en) * 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5277913A (en) * 1991-09-09 1994-01-11 Thompson David H Liposomal delivery system with photoactivatable triggered release
DE4132345A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Ether-lysolecithine und alkylphosphocholine in liposomen
EP0610289B1 (en) * 1991-10-23 1997-08-06 National Research Council Of Canada Formation of stable liposomes from lipid extracts of archaeobacteria (archaea)
DK0699068T3 (da) * 1993-05-21 2002-03-11 Liposome Co Inc Reduktion af liposominducerede fysiologiske bivirkninger
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie

Also Published As

Publication number Publication date
DK0785773T3 (da) 2001-01-29
FI971494A7 (fi) 1997-04-10
FI971494A0 (fi) 1997-04-10
EP0785773A1 (en) 1997-07-30
DE69519802D1 (de) 2001-02-08
NO971643L (no) 1997-06-09
DE69519802T2 (de) 2001-04-19
WO1996011670A1 (en) 1996-04-25
JPH10507450A (ja) 1998-07-21
FI971494L (fi) 1997-04-10
NO971643D0 (no) 1997-04-10
NO316206B1 (no) 2003-12-29
CA2199179A1 (en) 1996-04-25
ATE198419T1 (de) 2001-01-15
EP0785773B1 (en) 2001-01-03
KR100381449B1 (ko) 2003-07-18
AU707414B2 (en) 1999-07-08
PT785773E (pt) 2001-05-31
US5762958A (en) 1998-06-09
KR970705378A (ko) 1997-10-09
GR3035689T3 (en) 2001-07-31
AU3762595A (en) 1996-05-06

Similar Documents

Publication Publication Date Title
ES2153053T3 (es) Liposomas de eter-lipido y su uso terapeutico.
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
PA8481501A1 (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
ES2036593T3 (es) Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas.
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
ES2142353T3 (es) Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
ES2147294T3 (es) Compuestos terapeuticos.
ES2194392T3 (es) Derivados alfa-aminoamidicos utiles como agentes analgesicos.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9501848A (es) Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
ES2177594T3 (es) Combinaciones de sustancias y asoactivas con acidos grasos para prevenir la caida del cabello.
DK390585D0 (da) Kontrastmiddel og fremgangsmaade til anvendelse heraf
ES2063767T3 (es) Esteres aromaticos policiclicos de antibioticos macrolidicos y lincosamidicos, su procedimiento de preparacion y composiciones farmaceuticas y cosmeticas que los contienen.
ES2189961T3 (es) Un ensayo de diagnostico para la esquizofrenia que emplea niacina.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2181670T3 (es) Peptidos que conservan una actividad similar a la de la tromboespondina y su utilizacion terapeutica.
AR037766A1 (es) Compuestos triaromaticos analogos de la vitamina d, su utilizacion, composiciones farmaceuticas y cosmeticas que los comprenden y utilizacion cosmetica de dichas composiciones cosmeticas
ES2041617T3 (es) Productos intermedios para agentes de quelacion con simetria prefijada y procedimiento para su preparacion.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES541944A0 (es) Procedimiento para preparar liposomas que contiene alergenoso fracciones de alergenos inhalables

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 785773

Country of ref document: ES